Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays

OncoImmunology

Volumn 6, Issue 3, 2017, Pages

  Tosolini, Marie ^a,b,c,d,e   Pont, Frédéric ^a,b   Poupot, Mary ^a,b,c,d   Vergez, François ^a,b,e   Nicolau Travers, Marie Laure ^e   Vermijlen, David ^f   Sarry, Jean Emmanuel ^a,b,d   Dieli, Francesco ^g   Fournié, Jean Jacques ^a,b,c,d  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Laboratoire d Excellence TOUCAN   (France)

^d Programme Hospitalo Universitaire en Cancérologie CAPTOR   (France)

^e Institut Universitaire du Cancer de Toulouse   (France)

^f UNIVERSITY OF PALERMO   (Italy)

^g UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Artificial intelligence; cancer; data mining; deconvolution; gamma delta lymphocyte; machine learning; microarray; transcriptome

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; MALIGNANT NEOPLASM; MICROARRAY ANALYSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

EID: 85016586856     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1284723     Document Type: Article

References (57)

1. Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RL, Prieve A, Sosman JA, Lam VA, Sondel PM. Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med 1990; 171:1567–79; PMID:2185329; http://dx.doi.org/10.1084/jem.171.5.1567
2. Fournie JJ, Bonneville M. Stimulation of gamma delta T cells by phosphoantigens. Res Immunol 1996; 147:338–47; PMID:8876063; http://dx.doi.org/10.1016/0923-2494(96)89648-9
3. Poccia F, Malkovsky M, Gougeon ML, Bonneville M, Lopez-Botet M, Fournie JJ, Colizzi V. Gammadelta T cell activation or anergy during infections:the role of nonpeptidic TCR ligands and HLA class I molecules. J Leukoc Biol 1997; 62:287–91; PMID:9307066
4. Fournie JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F, Ysebaert L, Laurent G. What lessons can be learned from gamma delta T cell-based cancer immunotherapy trials? Cell Mol Immunol 2013; 10:35–41; http://dx.doi.org/10.1038/cmi.2012.39
5. Meraviglia S, Lo Presti E, Dieli F, Stassi G. gammadelta T cell-based anticancer immunotherapy:progress and possibilities. Immunotherapy 2015; 7:949–51; PMID:26569071; http://dx.doi.org/10.2217/imt.15.68
6. Kobayashi H, Tanaka Y. gammadelta T Cell Immunotherapy-A Review. Pharmaceuticals (Basel) 2015; 8:40–61; PMID:25686210; http://dx.doi.org/10.3390/ph8010040
7. Silva-Santos B, Serre K, Norell H. gammadelta T cells in cancer. Nat Rev Immunol 2015; 15:683–91; PMID:26449179; http://dx.doi.org/10.1038/nri3904
8. Shen-Orr SS, Gaujoux R. Computational deconvolution:extracting cell type-specific information from heterogeneous samples. Curr Opin Immunol 2013; 25:571–8; PMID:24148234; http://dx.doi.org/10.1016/j.coi.2013.09.015
9. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12:453–7; PMID:25822800; http://dx.doi.org/10.1038/nmeth.3337
10. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21:938–45; PMID:26193342; http://dx.doi.org/10.1038/nm.3909
11. Pont F, Familiades J, Dejean S, Fruchon S, Cendron D, Poupot M, Poupot R, L'faqihi-Olive F, Prade N, Ycart B, et al. The gene expression profile of phosphoantigen-specific human gammadelta T lymphocytes is a blend of alphabeta T-cell and NK-cell signatures. Eur J Immunol 2012; 42:228–40; PMID:21968650; http://dx.doi.org/10.1002/eji.201141870
12. Chtanova T, Newton R, Liu SM, Weininger L, Young TR, Silva DG, Bertoni F, Rinaldi A, Chappaz S, Sallusto F, et al. Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J Immunol 2005; 175:7837–47; PMID:16339519; http://dx.doi.org/10.4049/jimmunol.175.12.7837
13. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, Van Rysselberge M, Twité N, Goldman M, Marchant A, Willems F, et al. Human cytomegalovirus elicits fetal gammadelta T cell responses in utero. J Exp Med 2010; 207:807–21; PMID:20368575; http://dx.doi.org/10.1084/jem.20090348
14. Tosolini M, Algans C, Pont F, Ycart B, Fournie JJ. Large scale microarray profiling reveals four stages of immune escape in non-Hodgkin's lymphomas. Oncoimmunology 2016; 5(7):e1188246:in press; PMID:27622044; http://dx.doi.org/10.1080/2162402X.2016.1188246
15. Braza MS, Caraux A, Rousset T, Lafaye de Micheaux S, Sicard H, Squiban P, Costes V, Klein B, Rossi JF. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes. J Immunol 2010; 184:134–40; PMID:19949101; http://dx.doi.org/10.4049/jimmunol.0901980
16. Gaulard P, de Leval L. Pathology of peripheral T-cell lymphomas:where do we stand? Semin Hematol 2014; 51:5–16; PMID:24468311; http://dx.doi.org/10.1053/j.seminhematol.2013.11.003
17. Przybylski GK, Wu H, Macon WR, Finan J, Leonard DG, Felgar RE, DiGiuseppe JA, Nowell PC, Swerdlow SH, Kadin ME, et al. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. J Mol Diagn 2000; 2:11–9; PMID:11272897; http://dx.doi.org/10.1016/S1525-1578(10)60610-1
18. Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A, Charbonnier A, Collette Y, Vey N, Olive D. Human Vgamma9Vdelta2 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol 2012; 188:4701–8; PMID:22467661; http://dx.doi.org/10.4049/jimmunol.1103710
19. Gertner-Dardenne J, Fauriat C, Vey N, Olive D. Immunotherapy of acute myeloid leukemia based on gammadelta T cells. Oncoimmunology 2012; 1:1614–6; PMID:23264912; http://dx.doi.org/10.4161/onci.21512
20. Dean J, McCarthy D, Golden-Mason L, O'Farrelly C. Trephine biopsies are enriched for activated T/NK cells and cytotoxic T cells. Immunol Lett 2005; 99:94–102; PMID:15894117; http://dx.doi.org/10.1016/j.imlet.2005.01.008
21. Jack AS, Lu JQ. Immune cell infiltrates in the central nervous system tumors. Austin Neurosurgery:Open access 2015; 2(1):30
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis:a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545–50; PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102
23. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960–4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
24. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016; 44:698–711; PMID:26982367; http://dx.doi.org/10.1016/j.immuni.2016.02.025
25. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, Clark HF. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One 2009; 4:e6098; PMID:19568420; http://dx.doi.org/10.1371/journal.pone.0006098
26. Newman AM, Alizadeh AA. High-throughput genomic profiling of tumor-infiltrating leukocytes. Curr Opin Immunol 2016; 41:77–84; PMID:27372732; http://dx.doi.org/10.1016/j.coi.2016.06.006
27. Karpinski P, Frydecka D, Sasiadek MM, Misiak B. Reduced number of peripheral natural killer cells in schizophrenia but not in bipolar disorder. Brain Behav Immun 2016; 54:194–200; PMID:26872421; http://dx.doi.org/10.1016/j.bbi.2016.02.005
28. Wang QH, Muller F, Kim H, Squatrito M, Millelsen T, Scarpace L, Barthel F, Lin YH, Satani N, Martinez-Ledesma E, et al. Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment. bioRxiv 2016; http://dx.doi.org/https://doi.org/10.1101/052076
29. Araujo JM, Prado A, Cardenas NK, Zaharia M, Dyer R, Doimi F, Bravo L, Pinillos L, Morante Z, Aguilar A, et al. Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. Oncotarget 2016; 7:20282–92; PMID:26958810; http://dx.doi.org/10.18632/oncotarget.7943
30. Vinayak S, Gray RJ, Adams S, Jensen KC, Manola J, Afghahi A, Goldstein LJ, Ford JM, Badve SS, Telli ML. Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. J Clin Oncol 2014; 32:suppl.abstract 1000
31. Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, Schwartz T, Hunborg P, Varvares MA, Hoft DF, et al. Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. J Immunol 2012; 189:5029–36; PMID:23034170; http://dx.doi.org/10.4049/jimmunol.1201892
32. Kowalczyk D, Skorupski W, Kwias Z, Nowak J. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 1997; 80:543–7; PMID:9352689; http://dx.doi.org/10.1046/j.1464-410X.1997.00408.x
33. Bas M, Bier H, Schirlau K, Friebe-Hoffmann U, Scheckenbach K, Balz V, Whiteside TL, Hoffmann TK. Gamma-delta T-cells in patients with squamous cell carcinoma of the head and neck. Oral Oncol 2006; 42:691–7; PMID:16527515; http://dx.doi.org/10.1016/j.oraloncology.2005.11.008
34. Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, Mani VR, et al. gammadelta T cells support pancreatic oncogenesis by restraining alphabeta T cell activation. Cell 2016; 166:1485-99 e15; http://dx.doi.org/10.1016/j.cell.2016.07.046
35. Goorha R, Bunin N, Mirro J, Jr, Murphy SB, Cross AH, Behm FG, Quertermous T, Seidman J, Kitchingman GR. Provocative pattern of rearrangements of the genes for the gamma and beta chains of the T-cell receptor in human leukemias. Proc Natl Acad Sci U S A 1987; 84:4547–51; PMID:2955409; http://dx.doi.org/10.1073/pnas.84.13.4547
36. Buccheri V, Matutes E, Dyer MJ, Catovsky D. Lineage commitment in biphenotypic acute leukemia. Leukemia 1993; 7:919–27; PMID:8501986
37. Bachireddy P, Wu CJ. Understanding anti-leukemia responses to donor lymphocyte infusion. Oncoimmunology 2014; 3:e28187; PMID:25340010; http://dx.doi.org/10.4161/onci.28187
38. Aswald JM, Wang XH, Aswald S, Lutynski A, Minden MD, Messner HA, Keating A. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia:potential effector cells for immunotherapy? Cytometry B Clin Cytom 2006; 70:379–90; PMID:16977635; http://dx.doi.org/10.1002/cyto.b.20115
39. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, et al. gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014; 40:785–800; PMID:24816404; http://dx.doi.org/10.1016/j.immuni.2014.03.013
40. Zocchi MR, Ferrarini M, Migone N, Casorati G. T-cell receptor V delta gene usage by tumour reactive gamma delta T lymphocytes infiltrating human lung cancer. Immunology 1994; 81:234–9; PMID:8157272
41. Essand M, Vasmatzis G, Brinkmann U, Duray P, Lee B, Pastan I. High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate. Proc Natl Acad Sci U S A 1999; 96:9287–92; PMID:10430935; http://dx.doi.org/10.1073/pnas.96.16.9287
42. McNeel DG, Malkovsky M. Immune-based therapies for prostate cancer. Immunol Lett 2005; 96:3–9; PMID:15585302; http://dx.doi.org/10.1016/j.imlet.2004.06.009
43. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67:7450–7; PMID:17671215; http://dx.doi.org/10.1158/0008-5472.CAN-07-0199
44. Dieli F, Caccamo N, Meraviglia S. Advances in immunotherapy of castration-resistant prostate cancer:bisphosphonates, phosphoantigens and more. Curr Opin Investig Drugs 2008; 9:1089–94; PMID:18821471
45. Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, et al. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer 2013; 11:407–15; PMID:23835291; http://dx.doi.org/10.1016/j.clgc.2013.04.029
46. Rei M, Pennington DJ, Silva-Santos B. The emerging Protumor role of gammadelta T lymphocytes:implications for cancer immunotherapy. Cancer Res 2015; 75:798–802; PMID:25660949; http://dx.doi.org/10.1158/0008-5472.CAN-14-3228
47. Jin Z, Luo Q, Lu S, Wang X, He Z, Lai J, Chen S, Yang L, Wu X, Li Y. Oligoclonal expansion of TCR Vdelta T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia. J Hematol Oncol 2016; 9:126; PMID:27863523; http://dx.doi.org/10.1186/s13045-016-0353-3
48. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415–21; PMID:23945592; http://dx.doi.org/10.1038/nature12477
49. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214–8; PMID:23770567; http://dx.doi.org/10.1038/nature12213
50. Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, Dou R, Chen Q, Hodi FS, Choueiri TK, et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genetics 2016; 48:725–32; PMID:27240091; http://dx.doi.org/10.1038/ng.3581
51. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160:48–61; PMID:25594174; http://dx.doi.org/10.1016/j.cell.2014.12.033
52. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance. Cell 2016; 165:276–87; PMID:27058662; http://dx.doi.org/10.1016/j.cell.2016.03.001
53. Zitvogel L, Galluzzi L, Viaud S, Vetizou M, Daillere R, Merad M, Kroemer G. Cancer and the gut microbiota:an unexpected link. Sci Transl Med 2015; 7:271ps1; PMC4690201; http://dx.doi.org/10.1126/scitranslmed.3010473
54. Dimova T, Brouwer M, Gosselin F, Tassignon J, Leo O, Donner C, Marchant A, Vermijlen D. Effector Vgamma9Vdelta2 T cells dominate the human fetal gammadelta T-cell repertoire. Proc Natl Acad Sci U S A 2015; 112:E556–65; PMID:25617367; http://dx.doi.org/10.1073/pnas.1412058112
55. Bezanson J, Karpinski S, Shah VB, Edelman A. Julia:A fast dynamic language for technical computing. eprint arXiv:12095145 2012.
56. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9:811–8; PMID:2218183; http://dx.doi.org/10.1002/sim.4780090710
57. Therneau TM, Grambsch PM. Modeling survival data:Extending the cox model. New York:Springer, 2000.